USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
Acurx Pharmaceuticals, Inc. (ACXP)
Company Research
Source: PR Newswire
STATEN ISLAND, N.Y., Feb. 2, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that the United States Patent and Trademark Office has granted a new U.S. patent, US 12,534,470. This latest patent, which covers DNA Polymerase IIIC inhibitors including compositions-of-matter, methods of use, and pharmaceutical compositions, further strengthens Acurx's intellectual property portfolio and represents the most recent addition to its expanding series of granted patents in the U.S. and abroad. To date, Acurx has secured four U.S. patents, along with granted patents in Israel, Japan, India, and Australia, all of which protect key aspects of the Company's ACX-375C program targeting DNA Polymerase IIIC. Additional country-level patent applications remain under review.Robert J. DeLuccia, Executive Chairman
Show less
Read more
Impact Snapshot
Event Time:
ACXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACXP alerts
High impacting Acurx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ACXP
News
- USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors [Yahoo! Finance]Yahoo! Finance
- Acurx Pharmaceuticals (NASDAQ:ACXP) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACXP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Acurx Pharmaceuticals (NASDAQ:ACXP) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACXP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- Acurx Pharmaceuticals (NASDAQ:ACXP) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACXP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx PharmaceuticalsPR Newswire
ACXP
Earnings
- 11/12/25 - Beat
ACXP
Sec Filings
- 2/2/26 - Form S-1
- 1/7/26 - Form EFFECT
- 12/30/25 - Form S-3/A
- ACXP's page on the SEC website